This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good day, and thank you for standing by. Welcome to the Helios Medical Technologies, Inc. Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski, Investor Relations. Please go ahead.
spk00: Thank you, operator. Welcome to the second quarter 2023 earnings conference call for Helios Medical Technologies. This is Michelle Bilski of Insight Communications, Investor Relations for Helios. With me on today's call are Dane Andrees, Helios Medicals, President and Chief Executive Officer, and Jeff Mathieson, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the investor section of the Helios website at www.heliosmedicals.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that can cause actual results to differ materially from those indicated, including those identified in the risk factor section of our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. Such factors may be updated from time to time in our other filings with the FCC, which are available on our website. All statements made during the call are as of August 10th, 2023. The editor takes no obligation to publicly update or revise our forward-looking statements as a result of new information future events, or otherwise, except as required by law. I would now like to turn the call over to Dane Andrees, President and Chief Executive Officer of Helios.
spk19: Thank you, Michelle. Welcome, everyone, to Helios Medical's second quarter 2023 earnings conference call. I'm happy to report that we saw a significant increase in sales during the second quarter of 2023, with revenue up 115% compared to the prior year quarter. and up 131% compared to the first quarter of 2023. Increased U.S. sales of PON systems under the favorable pricing offered through the PTAP program, which terminated on June 30, 2023, in part drove the higher revenues, as did the ongoing addition of neurologists and trained PON-certified therapists recommending PONs to their patients. PONS therapy is a groundbreaking treatment for people suffering from balance and gait impairment. Since the beginning, our goal has been to get this important neurotechnology into the hands of as many qualified patients as possible by eliminating barriers to use. We launched PTAP one year ago to give qualified Americans suffering from balancing gate impairment due to MS, the ability to purchase ponds at a significantly reduced price, lessening the cost burden while we initiated efforts to pursue reimbursement by third-party payers and CMS. PTAP was initially scheduled to expire on December 31st, 2022, but due to the program's popularity, we extended it to June 30th. PTAP was a great success. By subsidizing PONS therapy for participants, we meaningfully reduced the major barrier to use and brought relief to a great number of patients than we otherwise would have. PTAP also enabled us to add to our MS patient registry. and collect important health economic information to establish the value of PONS on key clinical and therapeutic outcomes. This patient registry data is a key element to pursuing reimbursement. Going forward, sales of PONS systems will be on a cash basis as we continually to aggressively pursue coverage while also helping patients navigate the reimbursement pathway. As I mentioned before, we believe broad third-party payer reimbursement is needed to achieve our full revenue potential, and we remain very optimistic about CMS's Transitional Coverage of Emerging Technologies Program, or TSET, which is a proposed accelerated coverage pathway for new and innovative medical devices. In June, the CMS announced its proposed TCEP pathway and provided greater clarification on its approach to coverage reviews and evidence development. The proposed TCEP pathway would expedite Medicare coverage of certain breakthrough devices by allowing manufacturers the opportunity for increased pre-market engagement with CMS. Through premarket evaluation of technologies and identification of important evidence gaps, TSET aims to reduce uncertainty about coverage options. Under the new guidelines, qualifying breakthrough designations would have temporary coverage within six months after FDA market authorization, allowing companies greater time to gather the necessary clinical data to prove efficacy of their product and address any evidence gaps. This is great news for Helios as PONS has breakthrough designations in both MS and stroke in the United States. In addition, PONS was recently awarded durable medical equipment, prosthetics, orthotics and supplies, or DME POS accreditation by the compliance team, which is authorized by CMS to accredit all DME POS products and services. Organizations that wish to bill Medicare must have accreditation from an approved agency, and this certification is a key component in achieving coverage under TSET and if and when it's passed. As of now, we believe we are on a path toward achieving coverage in mid-2024, and we'll keep you updated on further developments. On our PONS Therapeutic Experience Program, otherwise known as PONSTEP, is another way we're bringing our technology to a greater number of patients suffering from balancing gait impairment. As a reminder, PONSTEP, is a company-sponsored open-label observational trial with a targeted enrollment of 50 to 60 patients that was designed to evaluate the impact of subjects' adherence to PONS therapy in patients with MS in a real-world setting. Earlier this week, we announced the addition of Montefiore Medical Center in Nyack, New York, to PONSTEP. Dr. Christopher Langston, who is leading the trial, is a renowned clinical researcher of current and advanced topics in MS management and was one of the first PONS prescribers. We expect Dr. Langston and his team at Madeline Borelli Multiple Sclerosis Center to be great contributors to the program. We now have six Centers of Excellence participating in PONS staff. with a goal of enrolling five to 10 patients per site. This is higher than the five patients per site we originally envisioned, as several of our sites are fully enrolled and interested in adding more patients. Enrollment in PondSTEP began during the fourth quarter of 2022 and will continue throughout 2023. We recently announced the expansion of our Medical University of South Carolina stroke trial from 12 to 60 patients. This investigator-initiated study evaluates the effects of cranial nerve noninvasive neuromodulation delivered using PON therapy on gait and dynamic balance in chronic stroke survivors. In Canada, where PONDS is already authorized for stroke, we've seen significant improvement in gait and a reduced risk of falling. This meaningful real-world data and expanded study are significant steps forward in our efforts to leverage the breakthrough designation and pursue approval for stroke in the United States. As a reminder, we previously were able to use results from similar clinical studies and World-World data to receive authorization for MS in the United States. Turning now to our Canadian activities, the timing of some orders and activity originally anticipated in the first half of 2023 has slipped into the second half of 2023, resulting in lower than expected Canadian revenues during the first six months of 2023. Having said that, we believe this timing difference will result in a stronger third quarter, which typically experiences seasonal weakness and a strong finish to the year. Because PONS is authorized in Canada for three indications, MS, stroke, and TBI, the market could be much larger than the U.S. market in the near term. Now, let me turn the call over to Jeff to discuss our second quarter financial results in detail.
spk09: Thanks, Dane. It is a pleasure to be with you today. Total revenue for the second quarter of 2023 was $256,000, an increase of $137,000 compared to the $119,000 in the second quarter of 2022. resulting from increased U.S. sales of pond systems primarily due to the favorable pricing offered through the PTAP, which terminated on June 30th. For the second quarter of 2023, cost of revenue was $184,000, compared to $88,000 for the prior year period, primarily attributable to the higher sales compared to the same period in the prior year. Selling general and administrative expenses for the second quarter of 2023 of $2.6 million were comparable to the $2.5 million reported in the second quarter of 2022. Research and development expenses for the second quarter of 2023 decreased to $0.7 million compared to $1 million in the second quarter of 2022. driven primarily by a decrease in product development expenses and clinical trial activities as the company transitioned to U.S. commercialization activities. Total operating expenses for the second quarter of 2023 decreased to $3.3 million compared to $3.5 million in the second quarter of 2022. Operating loss for the second quarter of 2023 was $3.2 million compared to a loss of $3.4 million for the prior year period. We reported a net loss for the second quarter of 2023 of $1.6 million, or a loss of six cents per basic and diluted common share, compared to a net loss of $3.8 million, or a loss of 97 cents per basic and diluted common share for the same period last year. Our cash burn from operations for the second quarter of 2023 was $2.7 million, compared to $3.7 million for the second quarter of 2022, reflecting the results of our focus on managing cash burn and extending our cash runway further into 2024. As of June 30, 2023, we had $8.6 million in cash and no debt. On June 23, 2023, the company entered into an agreement to create an at-the-market offering program, or ATM, under which the company may offer and sell shares, having an aggregate offering price of up to $2 million, providing Helios the ability to access additional cash opportunistically or on an as-needed basis. As of June 30, 2023, No issuances of securities have occurred in connection with the ATM. Turning now to our outlook. Management currently expects third quarter and full year 2023 revenue to be above the comparable periods in the prior year, with the shift in sales mix to be more heavily weighted in Canada, offsetting an anticipated decrease in the U.S. following the end of the PTAB. Future U.S. sales of ponds are expected to be at our cash pay price until we gain reimbursement by CMS and third-party payers. With that, operator, let's now open the call for questions.
spk06: Thank you, Jeff. We will now conduct the question and answer session. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question is from Jonathan Ashoff with Roth MKM. Please proceed.
spk10: Thank you. Good afternoon, guys. I was wondering, you know, how exactly does receiving DME POS accreditation alter your approach to seeking U.S. reimbursement? I mean, do you just mention it, or can you deal with payers in any materially different way?
spk19: Hi, Jonathan. This is Dean. Thank you for the question. You know, right now, we're actually looking at multiple paths, and just being DMA accredited and going towards CMS for coding and eventual reimbursement is just one pathway using the DME approach. The other pathway, of course, which we mentioned, the TCEP pathway, and we would also need the DME accreditation towards that. Regarding private payers, right now, given that we are in the process of collecting our codes, we are and will be doing more of going down the reimbursement pathway for patients on the miscellaneous code.
spk10: Okay. What can you say about the statistical power with 60 stroke patients in the stroke trial?
spk19: So, we have a data development plan in place. We're hopeful on increasing the number 60. We just haven't talked through that yet, Jonathan, but we're happy where we are at 60, and hopefully we could move that number up with our data development plan with the FDA.
spk10: Okay, and thank you. And lastly, how many more sites do you wish to add to PONSTEP, and when will we see any of those results, given that the June corporate slide deck on your website looks to be out of date? regarding timing for OnStep as well as the stroke trial, actually.
spk19: Yeah. We expect at least one to two more, Jonathan. And as you noted and we noted, that we're increasing the enrollment at each site, giving, you know, patients more than five devices, you know, per site now.
spk02: Okay.
spk19: Yeah.
spk10: That sounds great. That's all from me. Thank you.
spk02: Great. Thanks, Jonathan.
spk06: Thank you. Please stand by for the next question. Our next question comes from Jeff Cohen with Lattenberg, Thalm & Co. Please proceed.
spk05: Hi, Dane and Jeff. This is actually Destiny on for Jeff. Thank you for taking our questions. I guess I would like to kind of follow up On the previous question, that's a big step up from 12 patients to 60. And I'm wondering if you can just discuss a bit about the drivers of that increase.
spk19: Well, I think the drivers are really connected towards our breakthrough designation in stroke. That's our second one. We're definitely in the less than 1% of the medical device companies that have a breakthrough to have two breakthroughs. And we believe this stroke trial with Dr. Steve Coach at the University of South Carolina could potentially become much larger. And if so, potentially we will be able to use this data and other data to go down our breakthrough designation pathway with the FDA seeking authorization.
spk20: In stroke.
spk05: Okay. Got it. Got it. Okay. And then I'm curious, Jeff, maybe this one is for you. That revenue that was pushed into the second half of 2023, is that because of any macroeconomic factors you can call out, or is it simply just a timing of orders issue?
spk09: It's more the timing of orders issue. There's some things that have been – worked on in Canada that we had anticipated to play out earlier in the year that have slipped into the second half of the year. But, you know, they're still very active and we still expect them to happen. And so as we had planned out our year, it was just something that ended up slipping into the second half.
spk05: Okay, perfect. Thank you. And then can you talk a little bit about how the funnel looks currently, especially since you're moving away from kind of that subsidized price. Any changes there?
spk19: No changes. It's a very active funnel with our e-commerce site partnered with Upscript. Folks are still coming in. There's multiple ways patients interact with us. a lot of inquiries come right to Helios. And, of course, then with that interest and those questions answered for the U.S. patients that are on label, they would be directed to the e-commerce platform. And remember, the e-commerce platform does a number of things for the patient. It reduces the patient's time to get an appointment with their neurologist. That's a really big factor these days post-COVID. What we understand the average time to get an appointment with your neurologist is up to three months now, where having a telehealth, telemedicine site, e-prescribing site, you know, we're able to really allow the patient to get PONS therapy faster, quicker, and start their treatment with their physical therapist.
spk05: Okay, got it. Thank you. A couple more for me, if that's all right. Can you just remind me the timing on the T-set decisions?
spk19: So right now, we've got about 20 more days in the 60-day comment period. It's fast and furious. I've been on probably two calls a week with lobbyists and also some of our congressmen and senators. With this comment period, this is where we're really allowed to change the policy, which was written at CMS. And hopefully towards our favor, the medical device companies. You know, right now, without TSET, on average, it takes Scott Whitaker at Avamed said it takes on average 5.7 years for a medical device company to get reimbursement through CMF.
spk12: Wow, okay.
spk19: Yeah, that's a big number. Yeah, so T-SEDS is very important, not only for commercializing an MS and our reimbursement, but if you think about it, our second breakthrough in stroke, about 90% of stroke patients are covered by Medicare, by CMS.
spk05: Okay. All right. Got it. And then lastly, Can you call out any scientific conferences you'll be attending in the second half of 23 and maybe the first half of 2024? Yep.
spk19: We have one scheduled, but it's on the neurological physical therapy side. We will not be presenting any data there, but we'll be in the right place with neurologists and their neuro PTs.
spk05: Excellent. Thank you so much for taking our questions.
spk19: Thank you, Destiny. Thanks a lot.
spk06: Thank you. Please stand by for our next question. Our final question comes from Anthony Vendetti with Maxim Group. Please proceed.
spk13: Thanks. Hey, Dane and Jeff. Just in terms of... Hey, how you guys doing?
spk04: Can you...
spk13: Good, good. Can you talk about the distribution agreement that you signed with Health Tech Connex? How is that going? Is that starting to bear fruit? Can you just talk about where that's at at this point? And then have one follow up. Yeah.
spk09: Sure. Sure. This is Jeff. I'll take that question. So, again, we had an agreement with them previously, and we ended up entering into a new agreement that replaced the previous one. And so the agreement provides them exclusive distribution in Western Canada area. And, you know, that is something that is going well. We've got a good relationship with them. And so, you know, under the agreement, there are – purchase requirements that they have to make from us. And they also do a lot in working with us in promoting ponds. And as we're trying to establish other programs and reimbursement in Canada, we also are working with them to get insurance companies interested in reimbursing ponds in Canada. So They're a very strong partner, and that agreement is progressing well. Okay, great.
spk13: And then, you know, in terms of the e-commerce platform, how do you track or do you track the traffic that, you know, that you see there? You know, obviously that helps, right? helps you a lot in terms of, you know, reorders and so forth. Maybe just talk about what trends are you seeing on that platform?
spk19: Yeah, so in that funnel, there's about 12 steps that we track towards that funnel, Anthony. So, of course, we get a lot of inquiries. They come in, they fill out a questionnaire. You know, do they have MS? Yes. Do they have gait deficit? Yes. You know, there's a large questionnaire before they go down the pathway towards a telemedicine appointment. Some of them already have prescriptions and we use our online e-prescribing platform to dispense the product to the patient if they have a prescription. And then if they ask for an appointment, if they qualify, the doctor prescribes an e-prescription to them, they could have it filled that way we ship out the product, you know, that day, and they could have the product at their home within two days from that. You know, right now, like Jeff said, we expect a slower second half until we get reimbursement, but that doesn't slow the inquiries. The inquiries are very steady, you know, coming into not only our Helios website or phone number email inquiry, but we also get them to Upscripts, our partnership with Upscripts, to fulfill an order as well. So we track everything, Anthony. We track our Google searches and awareness there, what our brand's doing, what people are looking for, searching for. And really, you know, the biggest thing they're searching for is a viable treatment for balance and gait deficit. It comes across as the most common symptom in neurological diseases like MS. But, you know, Helios Medical and Pond's therapy gets picked up on Google searches now continuously, and we continuously see inquiries so that we can educate the patients.
spk13: Okay, okay, but the point being is until reimbursement, until there's reimbursement, you wouldn't be surprised if clicks to the site or visits to the site slowed a little bit in the second half.
spk19: I would say it would be constantly growing through the second half because you're talking about really, you know, getting through the first part of the funnel. And once we collect that inquiry and whether they're willing to pay cash, of course, or go down the reimbursement pathway, remember, the way we see it as we have that patient as a future PONS patient. It just might be delayed, you know, three to six months. Okay. unable to pay cash or go down the reimbursement pathway.
spk13: Okay. So they'll still be coming to – they'll still be visiting the site. It's just a matter of not whether the follow-through happens, depending on whether they elect to pay cash or they wait until the reimbursement, and at which point when that happens, the ones that are waiting, because you're tracking so many different metrics, you'll be able to reach out to them at that point.
spk20: Correct. That's correct.
spk13: Yeah. Okay. All right. Good. All right. Thanks. Thanks very much. Appreciate that. I'll hop back in the queue.
spk09: You bet. Anthony, I'll say one thing before you leave, just getting back to your first question. I did want to point out as you look in the 10Q and the sales breakdown, Canada for the U.S. You know, we've talked about the fact that Canada was lighter than expected, and you asked about the agreement with HTC. But I did want to point out that, you know, Canadian sales in the second quarter were more than double the first quarter level and were above the prior year comparable quarter level as well. So, you know, we are seeing good activity there. We just had some other things that we hadn't planned on that have gone into the second quarter. So second half of the year. Okay, great.
spk11: That's helpful, Collar. Thanks, Jeff. You bet.
spk06: Thank you. At this time, I would now like to turn the conference back to Dane for closing remarks.
spk19: Great. Thank you, Hope. And thank you, everyone, for following Helios Medical Technologies. We look forward to keeping you updated as we pursue coverage, reimbursement, and continue to bring PONS therapy to the millions who need it. Thank you.
spk06: This concludes today's conference call. Thank you for participating. You may now disconnect. Have a great evening. you Thank you. Thank you. Thank you. Good day, and thank you for standing by. Welcome to the Helios Medical Technologies, Inc. Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski, Investor Relations. Please go ahead.
spk00: Thank you, operator. Welcome to the second quarter 2023 earnings conference call for Helios Medical Technologies. This is Michelle Bilski of Insight Communications, Investor Relations for Helios. With me on today's call are Dane Andrees, Helios Medicals, President and Chief Executive Officer, and Jeff Mathieson, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the investor section of the Helios website at www.heliosmedicals.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that can cause actual results to differ materially from those indicated, including those identified in the risk factor section of our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. Such factors may be updated from time to time in our other filings with the FCC, which are available on our website. All statements made during the call are as of August 10th, 2023. The editor takes no obligation to publicly update or revise our forward-looking statements as a result of new information future events or otherwise, except as required by law. I would now like to turn the call over to Dane Andrees, President and Chief Executive Officer of Helios.
spk19: Thank you, Michelle. Welcome, everyone, to Helios Medical's second quarter 2023 earnings conference call. I'm happy to report that we saw a significant increase in sales during the second quarter of 2023, with revenue up 115% compared to the prior year quarter. and up 131% compared to the first quarter of 2023. Increased U.S. sales of PON systems under the favorable pricing offered through the PTAP program, which terminated on June 30, 2023, in part drove the higher revenues, as did the ongoing addition of neurologists and trained PON-certified therapists recommending PONs to their patients. PONS therapy is a groundbreaking treatment for people suffering from balance and gait impairment. Since the beginning, our goal has been to get this important neurotechnology into the hands of as many qualified patients as possible by eliminating barriers to use. We launched PTAP one year ago to give qualified Americans suffering from balance and gait impairment due to MS, the ability to purchase ponds at a significantly reduced price, lessening the cost burden while we initiated efforts to pursue reimbursement by third-party payers and CMS. PTAP was initially scheduled to expire on December 31st, 2022, but due to the program's popularity, we extended it to June 30th. PTAP was a great success. By subsidizing PONS therapy for participants, we meaningfully reduced the major barrier to use and brought relief to a great number of patients than we otherwise would have. PTAP also enabled us to add to our MS patient registry. and collect important health economic information to establish the value of PONS on key clinical and therapeutic outcomes. This patient registry data is a key element to pursuing reimbursement. Going forward, sales of PONS systems will be on a cash basis as we continually to aggressively pursue coverage while also helping patients navigate the reimbursement pathway. As I mentioned before, we believe broad third-party payer reimbursement is needed to achieve our full revenue potential, and we remain very optimistic about CMS's Transitional Coverage of Emerging Technologies Program, or TSET, which is a proposed accelerated coverage pathway for new and innovative medical devices. In June, the CMS announced its proposed TCEP pathway and provided greater clarification on its approach to coverage reviews and evidence development. The proposed TCEP pathway would expedite Medicare coverage of certain breakthrough devices by allowing manufacturers the opportunity for increased pre-market engagement with CMS. Through premarket evaluation of technologies and identification of important evidence gaps, TSET aims to reduce uncertainty about coverage options. Under the new guidelines, qualifying breakthrough designations would have temporary coverage within six months after FDA market authorization, allowing companies greater time to gather the necessary clinical data to prove efficacy of their product and address any evidence gaps. This is great news for Helios as PONS has breakthrough designations in both MS and stroke in the United States. In addition, PONS was recently awarded durable medical equipment, prosthetics, orthotics and supplies, or DME POS accreditation by the compliance team, which is authorized by CMS to accredit all DME POS products and services. Organizations that wish to bill Medicare must have accreditation from an approved agency, and this certification is a key component in achieving coverage under TSET, and if and when it's passed. As of now, we believe we're on a path toward achieving coverage in mid-2024, and we'll keep you updated on further developments. On our PONS Therapeutic Experience Program, otherwise known as PONSTEP, is another way we're bringing our technology to a greater number of patients suffering from balancing gait impairment. As a reminder, PONSTEP is a company-sponsored open-label observational trial with a targeted enrollment of 50 to 60 patients that was designed to evaluate the impact of subjects' adherence to PONS therapy in patients with MS in a real-world setting. Earlier this week, we announced the addition of Montefiore Medical Center in Nyack, New York, to PONSTEP. Dr. Christopher Langston, who is leading the trial, is a renowned clinical researcher of current and advanced topics in MS management and was one of the first PONS prescribers. We expect Dr. Langston and his team at Madeline Borelli Multiple Sclerosis Center to be great contributors to the program. We now have six Centers of Excellence participating in PONS staff. with a goal of enrolling five to 10 patients per site. This is higher than the five patients per site we originally envisioned, as several of our sites are fully enrolled and interested in adding more patients. Enrollment in PONSTEP began during the fourth quarter of 2022 and will continue throughout 2023. We recently announced the expansion of our Medical University of South Carolina stroke trial from 12 to 60 patients. This investigator-initiated study evaluates the effects of cranial nerve noninvasive neuromodulation delivered using PON therapy on gait and dynamic balance in chronic stroke survivors. In Canada, where PONS is already authorized for stroke, we've seen significant improvement in gait and a reduced risk of falling. This meaningful real-world data and expanded study are significant steps forward in our efforts to leverage the breakthrough designation and pursue approval for stroke in the United States. As a reminder, we previously were able to use results from similar clinical studies and world-world data to receive authorization for MS in the United States. Turning now to our Canadian activities, the timing of some orders and activity originally anticipated in the first half of 2023 has slipped into the second half of 2023, resulting in lower-than-expected Canadian revenues during the first six months of 2023. Having said that, we believe this timing difference will result in a stronger third quarter, which typically experiences seasonal weakness and a strong finish to the year. Because PONS is authorized in Canada for three indications, MS, stroke, and TBI, the market could be much larger than the U.S. market in the near term. Now, let me turn the call over to Jeff to discuss our second quarter financial results in detail.
spk09: Thanks, Dane. It is a pleasure to be with you today. Total revenue for the second quarter of 2023 was $256,000, an increase of $137,000 compared to the $119,000 in the second quarter of 2022, resulting from increased U.S. sales of pond systems primarily due to the favorable pricing offered through the PTAP, which terminated on June 30th. For the second quarter of 2023, cost of revenue was $184,000, compared to $88,000 for the prior year period, primarily attributable to the higher sales compared to the same period in the prior year. Selling general and administrative expenses for the second quarter of 2023 of $2.6 million were comparable to the $2.5 million reported in the second quarter of 2022. Research and development expenses for the second quarter of 2023 decreased to $0.7 million compared to $1 million in the second quarter of 2022. driven primarily by a decrease in product development expenses and clinical trial activities as the company transitioned to U.S. commercialization activities. Total operating expenses for the second quarter of 2023 decreased to $3.3 million compared to $3.5 million in the second quarter of 2022. Operating loss for the second quarter of 2023 was $3.2 million compared to a loss of $3.4 million for the prior year period. We reported a net loss for the second quarter of 2023 of $1.6 million, or a loss of 6 cents per basic and diluted common share, compared to a net loss of $3.8 million, or a loss of 97 cents per basic and diluted common share for the same period last year. Our cash burn from operations for the second quarter of 2023 was $2.7 million, compared to $3.7 million for the second quarter of 2022, reflecting the results of our focus on managing cash burn and extending our cash runway further into 2024. As of June 30, 2023, we had $8.6 million in cash and no debt. On June 23, 2023, the company entered into an agreement to create an at-the-market offering program, or ATM, under which the company may offer and sell shares, having an aggregate offering price of up to $2 million, providing Helios the ability to access additional cash opportunistically or on an as-needed basis. As of June 30, 2023, No issuances of securities have occurred in connection with the ATM. Turning now to our outlook. Management currently expects third quarter and full year 2023 revenue to be above the comparable periods in the prior year, with the shift in sales mix to be more heavily weighted in Canada, offsetting an anticipated decrease in the U.S. following the end of the PTAB. Future U.S. sales of ponds are expected to be at our cash pay price until we gain reimbursement by CMS and third-party payers. With that, operator, let's now open the call for questions.
spk06: Thank you, Jeff. We will now conduct the question and answer session. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question is from Jonathan Ashoff with Roth MKM. Please proceed.
spk10: Thank you. Good afternoon, guys. I was wondering, you know, how exactly does receiving DME POS accreditation alter your approach to seeking U.S. reimbursement? I mean, do you just mention it, or can you deal with payers in any materially different way?
spk03: Hi, Jonathan.
spk19: This is Dean. Thank you for the question. You know, right now, we're actually looking at multiple paths, and just being DMA accredited and going towards CMS for coding and eventual reimbursement is just one pathway using the DME approach. The other pathway, of course, which we mentioned, the TCEP pathway, and we would also need the DME accreditation towards that. Regarding private payers, you know, right now, given that we are in the process of collecting our codes, we are and will be doing more going down the reimbursement pathway for patients on the miscellaneous code.
spk10: Okay. What can you say about the statistical power with 60 stroke patients in the stroke trial?
spk19: So, we have a data development plan in place. We're hopeful on increasing the number 60. We just haven't talked through that yet, Jonathan, but we're happy where we are at 60, and hopefully we could move that number up with our data development plan with the FDA.
spk10: Okay, and thank you. And lastly, how many more sites do you wish to add to PONSTEP, and when will we see any of those results, given that the June corporate slide deck on your website looks to be out of date? regarding timing for OnStep as well as the stroke trial, actually.
spk19: Yeah. We expect at least one to two more, Jonathan. And as you noted and we noted, that we're increasing the enrollment at each site, giving, you know, patients more than five devices, you know, per site now.
spk02: Okay.
spk19: Yeah.
spk10: That sounds great. That's all from me. Thank you.
spk02: Great. Thanks, Jonathan.
spk06: Thank you. Please stand by for the next question. Our next question comes from Jeff Cohen with Lattenberg, Thalm & Co. Please proceed.
spk05: Hi, Dane and Jeff. This is actually Destiny on for Jeff. Thank you for taking our questions. I guess I would like to kind of follow up On the previous question, that's a big step up from 12 patients to 60. And I'm wondering if you can just discuss a bit about the drivers of that increase.
spk19: Well, I think the drivers are really connected towards our breakthrough designation in stroke. That's our second one. We're definitely in the less than 1% of the medical device companies that have a breakthrough to have two breakthroughs. And we believe this stroke trial with Dr. Steve Coach at the University of South Carolina could potentially become much larger. And if so, potentially we will be able to use this data and other data to go down our breakthrough designation pathway with the FDA seeking authorization.
spk05: in stroke okay got it got it um okay and then i'm curious uh jeff maybe this one is for you that revenue that was pushed into the second half of 2023 is that because of any macroeconomic factors you can call out or is it simply just a timing of orders issue it's more the timing of orders issue um there's some things that have been uh
spk09: worked on in Canada that we had anticipated to play out earlier in the year that have slipped into the second half of the year. But, you know, they're still very active and we still expect them to happen. And so as we had planned out our year, it was just something that ended up slipping into the second half.
spk05: Okay, perfect. Thank you. And then can you talk a little bit about how the funnel looks currently, especially since you're moving away from kind of that subsidized price. Any changes there?
spk19: No changes. It's a very active funnel with our e-commerce site partnered with Upscript. Folks are still coming in. There's multiple ways patients interact with us. a lot of inquiries come right to Helios. And, of course, then with that interest and those questions answered for the U.S. patients that are on label, they would be directed to the e-commerce platform. And remember, the e-commerce platform does a number of things for the patient. It reduces the patient's time to get an appointment with their neurologist. That's a really big factor these days post-COVID. What we understand the average time to get an appointment with your neurologist is up to three months now, where having a telehealth, telemedicine site, e-prescribing site, you know, we're able to really allow the patient to get PONS therapy faster, quicker, and start their treatment with their physical therapist.
spk05: Okay, got it. Thank you. A couple more for me, if that's all right. Can you just remind me, the timing on the T-set decisions
spk19: So right now, we've got about 20 more days in the 60-day comment period. It's fast and furious. I've been on probably two calls a week with lobbyists and also some of our congressmen and senators. With this comment period, this is where we're really allowed to change the policy, which was written at CMS. And hopefully towards our favor, the medical device companies. You know, right now, without TSET, on average, it takes Scott Whitaker at Avamed said it takes on average 5.7 years for a medical device company to get reimbursement through CMF.
spk12: Wow. Okay.
spk19: Yeah, that's a big number. Yeah. So T-SEDS is very important, not only for commercializing an MS and our reimbursement, but if you think about it, our second breakthrough in stroke, about 90% of stroke patients are covered by Medicare, by CMS.
spk05: Okay. All right. Got it. And then lastly, Can you call out any scientific conferences you'll be attending in the second half of 23 and maybe the first half of 2024? Yep.
spk19: We have one scheduled, but it's on the neurological physical therapy side. We will not be presenting any data there, but we'll be in the right place with neurologists and their neuro PTs.
spk05: Excellent. Thank you so much for taking our questions.
spk19: Thank you, Destiny. Thanks a lot.
spk06: Thank you. Please stand by for our next question. Our final question comes from Anthony Vendetti with Maxim Group. Please proceed.
spk13: Thanks. Hey, Dane and Jeff. Just in terms of... Hey, how you guys doing?
spk04: Can you
spk13: Good, good. Can you talk about the distribution agreement that you signed with Health Tech Connex? How is that going? Is that starting to bear fruit? Can you just talk about where that's at, at this point, and then have one follow up?
spk09: Sure. This is Jeff. I'll take that question. So again, we had an agreement with them previously, and we ended up entering into a new agreement that replaced the previous one. And so the agreement provides them the exclusive distribution in Western Canada area. And that is something that is going well. We've got a good relationship with them. And so under the agreement, there are... purchase requirements that they have to make from us. And they also do a lot in working with us in promoting ponds. And as we're trying to establish other programs and reimbursement in Canada, we also are working with them to get insurance companies interested in reimbursing ponds in Canada. So They're a very strong partner, and that agreement is progressing well. Okay, great.
spk13: And then, you know, in terms of the e-commerce platform, how do you track or do you track the traffic that, you know, that you see there? You know, obviously that helps, right? helps you a lot in terms of, you know, reorders and so forth. Maybe just talk about what trends are you seeing on that platform?
spk19: Yeah, so in that funnel, there's about 12 steps that we track towards that funnel, Anthony. So, of course, we get a lot of inquiries. They come in, they fill out a questionnaire. You know, do they have MS? Yes. Do they have gait deficit? Yes. You know, there's a large questionnaire before they go down the pathway towards a telemedicine appointment. Some of them already have prescriptions and we use our online e-prescribing platform to dispense the product to the patient if they have a prescription. And then if they ask for an appointment, if they qualify, the doctor prescribes an e-prescription to them, they could have it filled that way. we ship out the product, you know, that day, and they could have the product at their home within two days from that. You know, right now, like Jeff said, we expect a slower second half until we get reimbursement, but that doesn't slow the inquiries. The inquiries are very steady, you know, coming into not only our Helios website or phone number inquiry, phone number, email inquiry, but we also get them to Upscripts, our partnership with Upscripts, to fulfill an order as well. So we track everything, Anthony. We track our Google searches and awareness there, what our brand's doing, what people are looking for, searching for. And really, you know, the biggest thing they're searching for is a viable treatment for balance and gait deficit. It comes across as the most common symptom in neurological diseases like MS. But, you know, Helios Medical and Pond's therapy gets picked up on Google searches now continuously, and we continuously see inquiries so that we can educate the patients. Okay. Okay.
spk13: But the point being is until reimbursement, until there's reimbursement, you wouldn't be surprised if clicks to the site or visits to the site slowed a little bit in the second half.
spk19: I would say it would be constantly growing through the second half because you're talking about really, you know, getting through the first part of the funnel. And once we collect that inquiry and whether they're willing to pay cash, of course, or go down the reimbursement pathway, remember, the way we see it as we have that patient as a future PONS patient. It just might be delayed, you know, three to six months if there's unable to pay cash or go down the reimbursement pathway.
spk13: Okay. So they'll still be coming to – they'll still be visiting the site. It's just a matter of not whether the follow-through happens, depending on whether they elect to pay cash or they wait until the reimbursement, and at which point when that happens, the ones that are waiting, because you're tracking so many different metrics, you'll be able to reach out to them at that point.
spk20: Correct. That's correct.
spk13: Yeah. Okay. All right. Good. All right. Thanks. Thanks very much. Appreciate that. I'll hop back in the queue.
spk09: You bet. Anthony, I'll say one thing before you leave, just getting back to your first question. I did want to point out as you look in the 10Q and the sales breakdown, Canada for the U.S. You know, we've talked about the fact that Canada was lighter than expected, and you asked about the agreement with HTC. But I did want to point out that, you know, Canadian sales in the second quarter were more than double the first quarter level and were above the prior year comparable quarter level as well. So, you know, we are seeing good activity there. We just had some other things that we hadn't planned on that have gone into the second quarter. So second half of the year. Okay, great.
spk11: That's helpful, Collar. Thanks, Jeff. You bet.
spk06: Thank you. At this time, I would now like to turn the conference back to Dane for closing remarks.
spk19: Great. Thank you, Hope. And thank you, everyone, for following Helios Medical Technologies. We look forward to keeping you updated as we pursue coverage, reimbursement, and continue to bring PONS therapy to the millions who need it. Thank you.
spk06: This concludes today's conference call. Thank you for participating. You may now disconnect. Have a great evening.
Disclaimer